Since CDK4/6 inhibitors induce, in addition to a tumor cell cycle arrest, an enhanced antitumor immune response (36), they may be used in synergy with ICI to increase tumor immunogenicity (NCT02648477). Here, CDK4 is linked to neoplasm.